RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating
patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.
- Determine the effectiveness of imatinib mesylate in patients with recurrent Ewing's
family of tumors or desmoplastic small round-cell tumor.
- Determine the toxic effects of this drug in these patients.
- Determine the duration of disease-free and overall survival of patients treated with
OUTLINE: This is an open-label study.
Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
- Diagnosis of Ewing's family of tumors OR desmoplastic small round-cell tumor
- Must have immunohistochemical evidence of expression of greater than 2+/4+ for either
Kit (CD117) or platelet-derived growth factor receptor -a or -b
- No symptomatic brain metastases
- Asymptomatic brain metastases are allowed provided patient is not on concurrent
anticonvulsants or corticosteroids
- Over 16
- ECOG 0-2
- Not specified
- Absolute neutrophil count greater than 1,500/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin greater than 9 g/dL
- Bilirubin less than 1.5 times upper limit of normal (ULN)
- SGOT and SGPT less than 2.5 times ULN
- No chronic active hepatitis
- No cirrhosis
- No other acute or known chronic liver disease
- Creatinine less than 1.5 times ULN
- No concurrent poorly controlled or severe cardiovascular disease
- No concurrent poorly controlled or severe pulmonary disease
- HIV negative
- No concurrent poorly controlled or severe central nervous system disease
- No other concurrent poorly controlled or severe nonmalignant disease
PRIOR CONCURRENT THERAPY:
- Not specified
- At least 3 weeks since prior chemotherapy
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy
- More than 2 weeks since prior major surgery
- More than 28 days since prior investigational agents